期刊文献+

伊班膦酸钠治疗恶性肿瘤骨转移48例

原文传递
导出
摘要 目的观察恶性肿瘤骨转移患者应用伊班膦酸钠治疗后的病灶及临床症状缓解情况。方法采用开放、无对照的研究方法,48例患者第一周期连续静脉滴注3d伊班膦酸钠6mg,以后6mg/4周一次。结果骨转移病灶总有效率为47.92%;骨痛在第3、14天及2周期后的总有效率分别为68.75%、79.17%、72.92%,表现为波峰趋势,但无统计学意义(P〉0.05),治疗后高钙血症恢复正常,活动能力明显改善。结论负荷剂量伊班膦酸钠可以快速缓解疼痛,效果稳定,患者不良反应轻,可显著改善患者的生存质量。
出处 《肿瘤研究与临床》 CAS 2008年第11期775-777,共3页 Cancer Research and Clinic
  • 相关文献

参考文献13

  • 1张天泽 徐光炜.肿瘤学[M].天津:天津科学技术出版社,1996.1209.
  • 2Roodman GD. Mechanisms of bone metastasis[J]. N Engl J Med, 2004, 350(16): 1655-1664.
  • 3Van Poznak CH. The use of bisphosphonates in patients with breast cancer[J]. Cancer Control, 2002, 9(6): 480-489.
  • 4Finley RS. Bisphosphonates:elinieal experience[J]. Oncologist, 2004, 9(Suppl.4): 14-27.
  • 5Krempien R, Niethammer A, Harms W, et al. Bisphodphonates and bone metastases:current status and future directors [J]. Expert Rev Anticancer Ther, 2005, 5(2): 295-305.
  • 6Pecherstorfer M. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease [J]. Expert Opin Pharmacother, 2004, 5 (11): 2341-2350.
  • 7Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complication in patients with breast cancer and bone metastases [J]. Ann Oncol, 2003, 14(9): 1399-1405.
  • 8刘波,王哲海,孙雅红.伊班膦酸钠治疗恶性肿瘤骨转移疼痛的观察[J].肿瘤研究与临床,2004,16(5):340-341. 被引量:2
  • 9Johnson KB, Gable P, Kaime EM, et al. Significant deterioration in renal function with the new bisphosphonate,zoledronic acid[J]. J Clin Oncol, 2003, 22(Suppl,): 738(Abstract 2968).
  • 10Stein SH, Davidson E, Tweed A, et al. Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer [J]. J Clin Oncol, 2003, 22(Suppl.): 745(Abstract 2997).

二级参考文献10

  • 1王琳,秦叔逵,何泽明,陈映霞,邵志坚,沈健.国产帕米膦酸二钠治疗骨转移癌疼痛的临床观察[J].临床肿瘤学杂志,1997,2(4):12-14. 被引量:8
  • 2Menssen H D, Sakelova A, Fontana A, et al. Effects of longterm intravenous ibandronate the rapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma [J]. J Clin Oncol,2002,20 (9):2353 -2359.
  • 3Green J R, Muller K, Jaeggi K A. Preclinical Pharmacology of CGP42446. a new,potent, heterocyclic bisphosphophonate compound[J]. J Bone Miner Res, 1994,9(5):745-751.
  • 4Pecherstorfer M, Ludwing H, Schlosser K,et al. Administration of the bisphosphonate (BM 21.0955) by intravenous bolus injection[J]. J Bone Miner Res, 1996,14(5):587-593.
  • 5Coleman R E, Purohit O P, Black C, et al.Ibandronate: a well toierated new oral bisphosphonate for the treatment of bone metastases[J]. Breast, 1995,4(9):236.
  • 6Coleman R. Clinical aspects of metastatic bone disease. In: Coleman R, Rubens RD,eds, Metastatic Bone Diseases[M]. Camforht: The parhtenon publishing group Ltd,1992:11.
  • 7Rosen J R. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases[J]. Drugs,1996,51(4):537.
  • 8Jeal W, Barradell L B, Mctavish D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmentopausal osteoporosis [J]. Drugs,1997,53(3):415.
  • 9Boisser S, Magnetto S, Frappart L, et al.Bisphosphonate inhibit prostate and breast carcinoma cell adhesion to ummineralized and mineralized bone extra cellular matrices[J]. Cancer Res, 1997,57(18):3890.
  • 10任庆兰.骨转移癌疼痛治疗的现状[J].国外医学(肿瘤学分册),2001,28(4):312-314. 被引量:13

共引文献549

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部